Search

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Press release

The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018

June 12, 2018
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

March 26, 2019
ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

Press release

Yarrow Biotechnology, Inc., a newly formed biotechnology company backed by RTW Investments, LP, will lead development of the program ProQR

May 04, 2021
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Press release

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance the development of therapies for central nervous system diseases

January 05, 2024
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly

Press release

Companies will collaborate to develop editing oligonucleotides directed to up to five targets using ProQR’s proprietary Axiomer® RNA edit

September 08, 2021
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.

December 11, 2024
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Press release

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025 Axiomer activity demonstrated across multiple preclinical in vitro

March 29, 2023
ProQR Announces Second Quarter 2024 Operating and Financial Results

Press release

… milestones achieved in H1 related to progress in the Lilly partnership €96.2 million cash position as of end of Q2 … first half of the year. With the benefits of a productive partnership, a differentiated pipeline strategy rooted in …

August 08, 2024
ProQR Announces Year End 2023 Operating and Financial Results

Press release

… of Axiomer™ for CNS applications via new research partnership with Rett Syndrome Research Trust Completed … 2024 along with potential milestone income from existing partnership, and potential option to exercise for expansion …

March 13, 2024
ProQR Announces Year End 2024 Operating and Financial Results

Press release

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi

March 13, 2025